The Cellular and Molecular Immunotherapy in Prostate Cancer

Mukherjee, Anirban Goutam; Wanjari, Uddesh Ramesh; Prabakaran, D. S.; Ganesan, Raja; Renu, Kaviyarasi; Dey, Abhijit; Vellingiri, Balachandar; Kandasamy, Sabariswaran; Ramesh, Tharmalingam; Gopalakrishnan, Abilash Valsala

doi:10.3390/vaccines10081370

Cited by 14 publications

(8 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other immunopotentiating effects of RT include, but are not restricted to, M1 macrophage and T-cell accumulation into the tumor as well as the release of immunostimulatory adjuvants locally, all of which support the combination of RT with immunotherapy [ 30 , 31 , 32 , 33 , 34 ]. Clinical studies have also reported distant responses in patients receiving RT in combination with immune checkpoint inhibitors which were associated with alterations in circulating lymphocyte subsets and antibody responses to tumor-associated antigens [ 35 , 36 , 37 , 38 ]. In addition, there are studies to show changes in circulating immune cell subpopulations and cytokines in cancer patients after RT who did not receive systemic treatment [ 39 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy-Related Gene Signature in Prostate Cancer

Fortis

Goulielmaki

Aubert

et al. 2022

Cancers

View full text Add to dashboard Cite

Radiotherapy for localized prostate cancer has increased the cure and survival rates of patients. Besides its local tumoricidal effects, ionizing radiation has been linked to mechanisms leading to systemic immune activation, a phenomenon called the abscopal effect. In this study, we performed gene expression analysis on peripheral blood from prostate cancer patients obtained post- radiotherapy and showed that 6 genes, including CCR7, FCGR2B, BTLA, CD6, CD3D, and CD3E, were down-regulated by a range of 1.5–2.5-fold as compared to pre-radiotherapy samples. The expression of the signature consisting of these six genes was also significantly lower post- vs. pre-radiotherapy. These genes are involved in various tumor-promoting immune pathways and their down-regulation post-radiotherapy could be considered beneficial for patients. This is supported by the fact that low mRNA expression levels for the 6-gene signature in the prostate tumor tissue was linked to better survival. Importantly, we report that this 6-gene signature strongly correlated with a favorable prognosis regardless of poor standard clinicopathological parameters (i.e., Gleason score ≥ 8 and T3 (including T3a and T3b). Our pioneering data open the possibility that the 6-gene signature identified herein may have a predictive value, but this requires further long-term studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiotherapy-Related Gene Signature in Prostate Cancer

Fortis

Goulielmaki

Aubert

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…However, PCa cells treated with CM from PCa/adipocyte co-culture undergo remarkable metabolic reprogramming. However, PCa CM-treated adipocytes release a substantial amount of free glycerol and show an increase in the lipolytic enzyme adipose triglyceride lipase (ATGL), indicating a PCa-induced lipolytic phenotype [ 7 , 95 ]. Despite the lack of experimental proof in this scenario, it is well-established that glycerol participates in the glycolytic process to provide energy for cancer cells [ 96 , 97 , 98 ].…”

Section: Metabolic Regulation Of Pcamentioning

confidence: 99%

“…Simultaneously, PCa cells gradually re-activate mitochondrial phosphorylation with glucose metabolism, reducing citrate production. Androgen receptor (AR) in PCa supports metabolic and biosynthetic demands by reprogramming cellular metabolic pathways: mitochondrial respiration, aerobic glycolysis, and de novo lipogenesis [ 4 , 5 , 6 , 7 ]. Fatty acid (FA) synthesis may be an early event in prostate tumor formation and is also linked with disease progression [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Role of Metabolism and Metabolic Pathways in Prostate Cancer

et al. 2023

View full text Add to dashboard Cite

Prostate cancer (PCa) is the common cause of death in men. The pathophysiological factors contributing to PCa are not well known. PCa cells gain a protective mechanism via abnormal lipid signaling and metabolism. PCa cells modify their metabolism in response to an excessive intake of nutrients to facilitate advancement. Metabolic syndrome (MetS) is inextricably linked to the carcinogenic progression of PCa, which heightens the severity of the disease. It is hypothesized that changes in the metabolism of the mitochondria contribute to the onset of PCa. The studies of particular alterations in the progress of PCa are best accomplished by examining the metabolome of prostate tissue. Due to the inconsistent findings written initially, additional epidemiological research is required to identify whether or not MetS is an aspect of PCa. There is a correlation between several risk factors and the progression of PCa, one of which is MetS. The metabolic symbiosis between PCa cells and the tumor milieu and how this type of crosstalk may aid in the development of PCa is portrayed in this work. This review focuses on in-depth analysis and evaluation of the metabolic changes that occur within PCa, and also aims to assess the effect of metabolic abnormalities on the aggressiveness status and metabolism of PCa.

show abstract

“…DNA-Impfstoffe wurden im Tierversuch getestet, ihre Anwendung beim Menschen ist jedoch aufgrund des geringen Nutzen-Risiko-Verhältnisses umstritten [135]. Im Vergleich zu anderen Krebsimpfstoffen bieten sie einen neuartigen Ansatz [146], da sie keine infektiösen Erreger enthalten. Derzeit laufen mehrere klinische Phase-I-Studien [147, 148].…”

Section: Impfstoffbasierte Immuntherapieunclassified

Stand der Forschung und neue therapeutische Perspektiven in der Immuntherapie des Prostatakarzinoms

Maselli¹,

Giuliani²,

Laface³

et al. 2023

Kompass Onkol

View full text Add to dashboard Cite

Das Prostatakarzinom ist die häufigste Art von Tumor bei Männern. Im Frühstadium der Erkrankung ist es empfindlich gegenüber einer Androgenentzugstherapie. Bei Patienten mit metastasiertem kastrationssensitivem Prostatakarzinom (mHSPC) haben Chemotherapie und Androgenrezeptortherapien der zweiten Generation zu einer Verlängerung der Überlebenszeit geführt. Trotz der Fortschritte bei der Behandlung des mHSPC ist eine Kastrationsresistenz unvermeidlich, und viele Patienten entwickeln eine metastasierende kastrationsresistente Erkrankung (mCRPC). In den letzten Jahrzehnten hat die Immuntherapie die onkologische Landschaft dramatisch verändert und die Überlebensraten bei vielen Krebsarten erhöht. Allerdings hat die Immuntherapie beim Prostatakarzinom noch nicht die bahnbrechenden Ergebnisse gebracht, die sie bei anderen Tumorarten erzielt hat. Die Erforschung neuer Behandlungsmöglichkeiten ist für Patienten mit mCRPC aufgrund der schlechten Prognose sehr wichtig. In dieser Übersichtsarbeit konzentrieren wir uns auf die Gründe für die scheinbare intrinsische Resistenz des Prostatakarzinoms gegenüber der Immuntherapie, die Möglichkeiten zur Überwindung dieser Resistenz sowie die klinische Evidenz und auf neue therapeutische Perspektiven für die Immuntherapie des Prostatakarzinoms mit einem Blick in die Zukunft.

show abstract

The Cellular and Molecular Immunotherapy in Prostate Cancer

Cited by 14 publications

References 117 publications

Radiotherapy-Related Gene Signature in Prostate Cancer

Radiotherapy-Related Gene Signature in Prostate Cancer

Role of Metabolism and Metabolic Pathways in Prostate Cancer

Stand der Forschung und neue therapeutische Perspektiven in der Immuntherapie des Prostatakarzinoms

Contact Info

Product

Resources

About